Dementia Research: UK Trails Cancer by 20 Years

Dementia research in the UK is estimated to be at least 20 years behind the advancements seen in cancer research. In the last five years, England recruited only 551 participants into late-stage dementia trials, a stark contrast to the over 24,000 recruited for cancer trials.

This significant gap highlights the need for urgent action. The government has committed to publishing a Modern Service Framework for Frailty and Dementia this year, aiming to accelerate diagnosis and improve patient access to new treatments. There is a call for an ambitious target, similar to the 28-day cancer diagnosis goal, with 18 weeks proposed as a starting point.

Further challenges include the low rate of amyloid-positive diagnoses, with only 2% of patients informed about their status. Improving patient awareness of their rights and opportunities to join clinical trials is crucial. Despite a decline in trial launches, recent government investment, including £50 million for the Dementia Trials Network (UKDTN) in 2024, has improved the situation.

With sustained investment and a focus on research, the UK has the potential to become a world leader in both early and late-phase clinical trials. This will ensure that NHS patients can access innovations without significant delays compared to countries like the US and Japan. The Modern Service Framework is viewed as a critical opportunity to enhance diagnosis and benefit from research breakthroughs.

Charities like the Alzheimer's Society are investing heavily, calling for continued government support. Patient participation is essential, as demonstrated by individuals like Stuart Jennings' late wife, Carol, whose involvement in research in the late 1980s contributed to the formulation of the "amyloid hypothesis." This highlights how volunteer efforts drive progress towards better diagnosis, treatments, and ultimately, a cure for dementia.